Biocept (NASDAQ:BIOC) is an oncology diagnostics company with one commercially available test (OncoCEE-BR for breast cancer).
Better detection for better treatment
There is an unmet need for an alternative to an invasive tissue biopsy given the inherent drawbacks. For example, as different parts of the same tumor can have different molecular features, this increases the potential for the pathologist to miss important biomarkers (used to determine the most appropriate treatment) as only a few thin slices of the tumor are analyzed. The mutation of tumors during treatment or disease progression may result in the initial tumor tissue being irrelevant. It may be impossible to even conduct a biopsy in certain cases such as when the cancer...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|